Nerve repair breakthrough? tesamorelin trial aims to boost hand recovery

NCT ID NCT03150511

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether tesamorelin, a daily self-injected drug, can speed nerve regrowth and reduce muscle loss after surgical repair of injured nerves in the arm. 36 adults with a cut ulnar nerve at the wrist will be randomly assigned to receive tesamorelin or no additional treatment. Researchers will measure pinch strength, hand function, and nerve signals every 3 months for a year to see if the drug improves recovery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Tesamorelin (Egrifta) – a daily self-injected drug
What this could lead to
If it works, this could point toward a treatment that helps people recover more hand strength and sensation after nerve injury surgery.
What could go wrong
This is a small, early-phase trial with only 36 people, so results may not apply broadly. Tesamorelin is not approved for nerve injury and may have side effects like injection site reactions or affect blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PERIPHERAL NERVE INJURIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sami Tuffaha

    RECRUITING

    Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.